Research progress of myeloperoxidase in cardiovascular diseases

doi:10.3969/j.issn.1673-8640.2017.08.018

Abstract

Abstract:

Myeloperoxidase（MPO）which exists in myeloid cells（mainly in neutrophils and monocytes）,is an enzyme derived of leukocytes that catalyzes the formation of numerous reactive oxidant species. Besides innate in defense function,current knowledge has been proved the contribution of these oxidants to tissue injury during inflammation,and MPO plays an important role in the initiation,propagation and acute complications of atherosclerotic process. Growing researches demonstrate the action of MPO as central participant of the link in nitric oxide,lipid metabolism and acute coronary syndrome. This review focuses on the research progress of MPO in cardiovascular diseases.

Key words: Myeloperoxidase, Atherosclerosis, Acute coronary syndrome

CLC Number:

R446.1

BO Lei, SHAN Jigang, ZHAO Zhiwen. Research progress of myeloperoxidase in cardiovascular diseases[J]. Laboratory Medicine, 2017, 32(8): 738-743.

Figures/Tables 2

References 38

[1]	PODREZ E A, ABU-SOUD H M,HAZEN S L. Myeloperoxidase-generated oxidants and atherosclerosis[J]. Free Radic Biol Med,2000,28(12):1717-1725.
[2]	CARR A C,MYZAK M C,STOCKER R,et al.Myeloperoxidase binds to low-density lipoprotein:potential implications for atherosclerosis[J]. FEBS Lett,2000,487(2):176-180.
[3]	APPLE F S,WU A H,MAIR J,et al.Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome[J]. Clin Chem,2005,51(5):810-824.
[4]	FU X,KASSIM S Y,PARKS W C,et al.Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin(MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase[J]. J Biol Chem,2001,276(44):41279-41287.
[5]	SHABANI F,MCNEIL J,TIPPETT L.The oxidative inactivation of tissue inhibitor of metalloproteinase-1(TIMP-1)by hypochlorous acid(HOCI)is suppressed by anti-rheumatic drugs[J]. Free Radic Res,1998,28(2):115-123.
[6]	ROSS R.Atherosclerosis-an inflammatory disease[J]. N Engl J Med,1999,340(2):115-126.
[7]	NICHOLLS S J,HAZEN S L.Myeloperoxidase and cardiovascular disease[J]. Arterioscler Thromb Vasc Biol,2005,25(6):1102-1111.
[8]	BRENNAN M L,HAZEN S L.Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment[J]. Curr Opin Lipidol,2003,14(4):353-359.
[9]	KOETH R A,HASELDEN V,TANG W H.Myeloperoxidase in cardiovascular disease[J]. Adv Clin Chem,2013,62:1-32.
[10]	LAKSHMI V M,NAUSEEF W M,ZENSER T V.Myeloperoxidase potentiates nitric oxide-mediated nitrosation[J]. J Biol Chem,2005,280(3):1746-1753.
[11]	VITA J A,BRENNAN M L,GOKCE N,et al.Serum myeloperoxidase levels independently predict endothelial dysfunction in humans[J]. Circulation,2004,110(9):1134-1139.
[12]	ABU-SOUD H M,HAZEN S L. Nitric oxide is a physiological substrate for mammalian peroxidases[J]. J Biol Chem,2000,275(48):37524-37532.
[13]	DELPORTE C,VAN ANTWERPEN P,VANHAMME L,et al.Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies[J]. Mediators Inflamm,2013,2013:971579.
[14]	EXNER M,HERMANN M,HOFBAUER R,et al.Thiocyanate catalyzes myeloperoxidase-initiated lipid oxidation in LDL[J]. Free Radic Biol Med,2004,37(2):146-155.
[15]	ZHANG R,BRENNAN M L,SHEN Z,et al.Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation[J]. J Biol Chem,2002,277(48):46116-46122.
[16]	PODREZ E A,SCHMITT D,HOFF H F,et al.Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro[J]. J Clin Invest,1999,103(11):1547-1560.
[17]	ZHANG X,DONG L,WANG Q,et al.The relationship between fasting plasma glucose and MPO in patients with acute coronary syndrome[J]. BMC Cardiovasc Disord,2015,15:93.
[18]	GRANÉR M,TIKKANEN E,RIMPILÄ O,et al. Diagnostic efficacy of myeloperoxidase to identify acute coronary syndrome in subjects with chest pain[J]. Ann Med,2013,45(4):322-327.
[19]	MEHTA M D,MARWAH S A,GHOSH S,et al.A synergistic role of myeloperoxidase and high sensitivity troponin T in the early diagnosis of acute coronary syndrome[J]. Indian J Clin Biochem,2016,31(1):75-80.
[20]	FONG S W,FEW L L,SEE TOO W C,et al. Systemic and coronary levels of CRP,MPO,sCD40L and PIGF in patients with coronary artery disease[J]. BMC Res Notes,2015,8:679.
[21]	VASILJ M,STARCEVIC B,VOLARIC M,et al.Diagnostic value of MPO in patients admitted for suspected acute coronary syndrome-a study of adult in Mostar,Bosnia and Herzegovina[J]. Coll Antropol,2014,38(1):213-217.
[22]	OEMRAWSINGH R M,LENDERINK T,AKKERHUIS K M,et al.Multimarker risk model containing troponin-T,interleukin 10,myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome[J]. Heart,2011,97(13):1061-1066.
[23]	POPE J H,AUFDERHEIDE T P,RUTHAZER R,et al.Missed diagnoses of acute cardiac ischemia in the emergency department[J]. N Engl J Med,2000,342(16):1163-1170.
[24]	SEARLE J,SHIH J,MULLER R,et al.The role of myeloperoxidase(MPO)for prognostic evaluation in sensitive cardiac troponin I negative chest pain patients in the emergency department[J]. Eur Heart J Acute Cardiovasc Care,2013,2(3):203-210.
[25]	GEDIKLI O,KIRIS A,HOSOGLU Y,et al.Serum myeloperoxidase level is associated with heart-type fatty acid-binding protein but not troponin T in patients with chronic heart failure[J]. Med Princ Pract,2015,24(1):42-46.
[26]	CABASSI A,BINNO S M,TEDESCHI S,et al.Myeloperoxidase-related chlorination activity is positively associated with circulating ceruloplasmin in chronic heart failure patients:relationship with neurohormonal,inflammatory,and nutritional parameters[J]. Biomed Res Int,2015,2015:691693.
[27]	REICHLIN T,SOCRATES T,EGLI P,et al.Use of myeloperoxidase for risk stratification in acute heart failure[J]. Clin Chem,2010,56(6):944-951.
[28]	YUNOKI K,NARUKO T,INABA M,et al.Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease[J]. Atherosclerosis,2013,231(2):308-314.
[29]	STEFANESCU A,BRAUN S,NDREPEPA G,et al.Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease[J]. Am Heart J,2008,155(2):356-360.
[30]	WENG K P,HSIEH K S,HUANG S H,et al.Myeloperoxidase genetic polymorphisms and susceptibility to Kawasaki disease in Taiwanese children[J]. J Microbiol Immunol Infect,2016,49(5):788-796.
[31]	LI J,FU Y,ZHAO B,et al.Myeloperoxidase G463A polymorphism and risk of lung cancer[J]. Tumour Biol,2014,35(1):821-829.
[32]	CHEN L,ZHAO S,CHENG G,et al.Meta-analysis of myeloperoxidase gene polymorphism and coronary artery disease susceptibility[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban,2014,39(3):217-231.
[33]	HOU X,GAO Y,DUAN Y,et al.The association between myeloperoxidase 463G>A polymorphisms and risk of lung cancer in East-Asia population[J]. J Cancer Res Ther,2015,11(Suppl 1):C97-C100.
[34]	NATTER C,POLTERAUER S,PILS S,et al.Association of -463G/A MPO gene polymorphism and risk of cervical intraepithelial neoplasia[J]. Arch Gynecol Obstet,2016,293(4):865-869.
[35]	MEHANNA E T,SALEH S M,GHATTAS M H,et al.Relation of myeloperoxidase-463G/A polymorphism with metabolic syndrome and its component traits in Egyptian women[J]. Arch Physiol Biochem,2015,121(1):13-18.
[36]	NDREPEPA G,BRAUN S,SCHÖMIG A,et al. Impact of therapy with statins,beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease[J]. Clin Res Cardiol,2011,100(4):327-333.
[37]	ROBERTS C K,WON D,PRUTHI S,et al.Effect of a short-term diet and exercise intervention on oxidative stress,inflammation,MMP-9,and monocyte chemotactic activity in men with metabolic syndrome factors[J]. J Appl Physiol(1985),2006,100(5):1657-1665.
[38]	CHANG P Y,WU T L,HUNG C C,et al.Development of an ELISA for myeloperoxidase on microplate:normal reference values and effect of temperature on specimen preparation[J]. Clin Chim Acta,2006,373(1-2):158-163.